Labiotech.eu

News and Trends 23 Nov 2022

Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma

An impressive crowd gathered at Chiesi Pharmaceutical Group yesterday (November 21) to mark the much-anticipated start of work at its Biotech Center of Excellence, bringing the future of medicine to Parma. Guests, which included Vice Minister of Business and Made in Italy, Valentino Valentini, joined to celebrate the start of the work on the building, […]

November 23, 2022 - 5 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

First patients dosed with Infex Therapeutics’ RESP-X for chronic respiratory disease

A new anti-virulence therapy, RESP-X, treating Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients has been given to the first subjects in a trial run by Infex Therapeutics. Infex Therapeutics is an anti-infectives company and announced the first subjects were dosed in the phase 1 study in healthy volunteers evaluating the company’s lead […]

November 23, 2022 - 3 minutesmins - By Liza Laws

More News! 23 Nov 2022

Novo Nordisk announces $750M facility expansion

Novo Nordisk has announced plans to invest DKK 5.4 bn ($750m) in the expansion of existing facilities in Bagsværd, Denmark. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply global […]

November 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

Tevogen Bio to investigate T cell therapy in long Covid

Tevogen Bio is set to study the potential therapeutic use of its investigational Covid-19 T cell therapy, TVGN-489, in long Covid. The finding that none of the patients in the TVGN 489 proof-of-concept (POC) trial, treated for their initial Covid infection, developed long Covid to date is leading Tevogen to explore the potential of TVGN […]

November 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

FDA approves CSL gene therapy for hemophilia B

CSL has revealed that the U.S. Food and Drug Administration (FDA) has approved HEMGENIX (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B. HEMGENIX is approved for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage or […]

November 23, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 22 Nov 2022

Achilles Therapeutics receives US patent for immunotherapies

A U.S. patent has been granted to Achilles Therapeutics plc for the treatment of patients with an immunotherapy, including vaccine, antibody and autologous T cell therapy approaches, targeting clonal neoantigens identified using the Achilles Clonality Engine (ACE). ACE is a proprietary method for determining clonality of patient-specific mutations that drives the PELEUS bioinformatics platform. Clonal […]

November 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Nov 2022

CatalYm raises €50M to boost solid tumors trial

CatalYm has announced the close of a €50 million ($49 million) series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the clinical development of its […]

November 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Nov 2022

Arecor to start second type 2 diabetes clinical trial

Arecor Therapeutics plc says the BASG (Bundesamt für Sicherheit im Gesundheitswesen) has cleared the company’s clinical trial application (CTA) for AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate, in type 2 diabetic patients. The CTA approval means Arecor can start its second phase I clinical trial for AT278. AT278 has previously demonstrated a faster […]

November 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Nov 2022

FogPharma raises $178M to target cancer

U.S biotech company FogPharma has announced a $178 million series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts advised by T. Rowe Price Associates, Inc., Invus, Farallon Capital Management, […]

November 21, 2022 - 4 minutesmins - By Jim Cornall

Startup Scout 21 Nov 2022

Osivax is designing future-proof influenza and Covid vaccines

Viruses causing influenza and COVID-19 continually evolve to escape our vaccine protections. The French firm Osivax is developing vaccines that are harder for the viruses to evade. Many life-saving vaccines have been developed and approved to protect against viral infections including COVID-19 and influenza. Commercially available vaccines typically activate the production of antibodies against fragments […]

November 21, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 21 Nov 2022

Legend Biotech small cell lung cancer drug gets FDA ok for clinical development

Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s investigational new drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adult patients with extensive stage small cell lung cancer (SCLC). LB2102 is […]

November 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Nov 2022

Immorna cleared for mRNA-based Covid-19 vaccine study

U.S. biotech company Immorna says the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a phase 1/2 multi-center study of JCXH-221, a lipid nanoparticle (LNP) complexed broadly protective mRNA vaccine against SARS-CoV-2 infection and diseases. The goal of the multi-center study is to assess the safety and immunogenicity […]

November 21, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma

First patients dosed with Infex Therapeutics’ RESP-X for chronic respiratory disease

Novo Nordisk announces $750M facility expansion

Tevogen Bio to investigate T cell therapy in long Covid

FDA approves CSL gene therapy for hemophilia B

Achilles Therapeutics receives US patent for immunotherapies

CatalYm raises €50M to boost solid tumors trial

Arecor to start second type 2 diabetes clinical trial

FogPharma raises $178M to target cancer

Osivax is designing future-proof influenza and Covid vaccines

Legend Biotech small cell lung cancer drug gets FDA ok for clinical development

Immorna cleared for mRNA-based Covid-19 vaccine study

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!